SEVERE TOXICITY IN A PATIENT WITH ACUTE LYMPHOBLASTIC LEUKAEMIA RESULTING FROM SUBSTITUTION OF DAUNORUBICIN WITH DOXORUBICIN DUE TO MEDICINE SHORTAGE: A CASE REPORT

M. MUNZ1, N. STEINER2, C. UPRIMNY3, C. PETTER1, D. WOLF1, D. NACHBAUR1, M. JESKE1.
1INNSBRUCK UNIVERSITY HOSPITAL, PHARMACY DEPARTMENT, AUSTRIA.
2INNSBRUCK UNIVERSITY HOSPITAL, DEPARTMENT OF INTERNAL MEDICINE V HAEMATOLOGY AND ONCOLOGY, AUSTRIA.
3INNSBRUCK UNIVERSITY HOSPITAL, PHARMACY DEPARTMENT, DEPARTMENT OF NUCLEAR MEDICINE, AUSTRIA.

BACKGROUND AND IMPORTANCE

• We present the case of a young patient with T-lymphoblastic lymphoma (T-LBL) who developed severe toxicity after receiving an anthracycline-based protocol, that is generally well tolerated by fit patients.
• We assume that the substitution of daunorubicin by doxorubicin due to a nationwide shortage of daunorubicin has played a crucial role in developing severe toxicity.

AIM AND OBJECTIVES

• The 19-year-old male with no previous illnesses was diagnosed in December 2019 with T-LBL - a rare, aggressive neoplasm of precursor T cells that progresses rapidly and requires prompt diagnosis and medical intervention.
• Figure 1: glucose-hypermetabolic mediastinal mass (FDG-PET/CT, December 2019)

MATERIAL AND METHODS

• The induction protocol consisted of dexamethasone, vincristine, daunorubicin, and pegasparaginase.
• Due to a nationwide shortage, daunorubicin (30mg/m²) was substituted by doxorubicin (25mg/m²).
• Figure 2: exemplary illustration of drug shortages in hematology and oncology (adapted from reference 1)

RESULTS

• Chemotherapy was initially well-tolerated, but beginning on day 15, the patient developed pronounced mucositis and increased skin toxicity (hand-foot-syndrome, grade IV). Moreover, coagulation parameters deteriorate, and repeated transfusions with erythrocytes and platelet concentrates were needed.
• After administration of pegasparaginase on day 31, liver values increased, and finally, the patient had to be transferred to the intensive care unit due to fulminant pancreatitis.
• After three days, the patient could be transferred back to our ward. Still, within two weeks, the patient developed sensory disturbances in all extremities, which was classified as chemotherapy-associated polyneuropathy.
• In the further clinical course, the patient’s general condition improved, and a PET-CT showed complete metabolic remission.
• Figure 2: complete metabolic remission (FDG-PET/CT, January 2020)

• Due to the severe chemotherapy-associated side effects, intensive consolidation treatment, according to the protocol was canceled. Instead, a consolidating therapy with nelarabine was carried out without complications. Until now (February 2021), the patient is in good clinical condition and has neither developed a disease recurrence.
• Probability assessment using the Naranjo algorithm (reference 2) resulted in “probable adverse drug reaction” (score=6).

CONCLUSION AND RELEVANCE

Our case report underlines that shortages of essential anticancer drugs have a particular impact on established chemotherapy regimens’ efficacy and safety, as these medicines often have few or no proven effective alternatives.

Contact information:
Dr. rer. nat. Martin Munz
Zentraler Zytostatika Service / Klinische Pharmazie
Apotheker des A.Ö. Landeskrankenhaus – Univ.-Kliniken Innsbruck
Tirol Kliniken GmbH – www.tirol-kliniken.at
Email: martin.munz@tirol-kliniken.at

References: